Sort by
Items per page

Send to

Choose Destination

Search results

Items: 9


PDCB does not promote CNS autoimmunity in the context of genetic susceptibility but worsens its outcome.

Dubey D, Hussain RZ, Miller-Little WA, Salter A, Doelger R, Stüve O.

J Neuroimmunol. 2018 Oct 15;323:53-55. doi: 10.1016/j.jneuroim.2018.07.012. Epub 2018 Jul 25.


Defining standard enzymatic dissociation methods for individual brains and spinal cords in EAE.

Hussain RZ, Miller-Little WA, Doelger R, Cutter GR, Loof N, Cravens PD, Stüve O.

Neurol Neuroimmunol Neuroinflamm. 2018 Jan 17;5(2):e437. doi: 10.1212/NXI.0000000000000437. eCollection 2018 Mar.


Laquinimod has no effects on brain volume or cellular CNS composition in the F1 3xTg-AD/C3H mouse model of Alzheimer's disease.

Hussain RZ, Miller-Little WA, Lambracht-Washington D, Jaramillo TC, Takahashi M, Zhang S, Fu M, Cutter GR, Hayardeny L, Powell CM, Rosenberg RN, Stüve O.

J Neuroimmunol. 2017 Aug 15;309:100-110. doi: 10.1016/j.jneuroim.2017.05.017. Epub 2017 May 26.


Biochemical and Cellular Determinants of Renal Glomerular Elasticity.

Embry AE, Mohammadi H, Niu X, Liu L, Moe B, Miller-Little WA, Lu CY, Bruggeman LA, McCulloch CA, Janmey PA, Miller RT.

PLoS One. 2016 Dec 12;11(12):e0167924. doi: 10.1371/journal.pone.0167924. eCollection 2016.


IL-12/IL-23p40 Is Highly Expressed in Secondary Lymphoid Organs and the CNS during All Stages of EAE, but Its Deletion Does Not Affect Disease Perpetuation.

Cravens PD, Hussain RZ, Miller-Little WA, Ben LH, Segal BM, Herndon E, Stüve O.

PLoS One. 2016 Oct 25;11(10):e0165248. doi: 10.1371/journal.pone.0165248. eCollection 2016.


A Single Amino Acid Substitution Prevents Recognition of a Dominant Human Aquaporin-4 Determinant in the Context of HLA-DRB1*03:01 by a Murine TCR.

Arellano B, Hussain R, Miller-Little WA, Herndon E, Lambracht-Washington D, Eagar TN, Lewis R, Healey D, Vernino S, Greenberg BM, Stüve O.

PLoS One. 2016 Apr 7;11(4):e0152720. doi: 10.1371/journal.pone.0152720. eCollection 2016.


Dimethyl fumarate in relapsing-remitting multiple sclerosis: rationale, mechanisms of action, pharmacokinetics, efficacy and safety.

Dubey D, Kieseier BC, Hartung HP, Hemmer B, Warnke C, Menge T, Miller-Little WA, Stuve O.

Expert Rev Neurother. 2015 Apr;15(4):339-46. doi: 10.1586/14737175.2015.1025755. Review.


Clinical management of multiple sclerosis and neuromyelitis optica with therapeutic monoclonal antibodies: approved therapies and emerging candidates.

Dubey D, Kieseier BC, Hartung HP, Hemmer B, Miller-Little WA, Stuve O.

Expert Rev Clin Immunol. 2015 Jan;11(1):93-108. doi: 10.1586/1744666X.2015.992881. Epub 2014 Dec 15. Review.


MUPP1 complexes renal K+ channels to alter cell surface expression and whole cell currents.

Sindic A, Huang C, Chen AP, Ding Y, Miller-Little WA, Che D, Romero MF, Miller RT.

Am J Physiol Renal Physiol. 2009 Jul;297(1):F36-45. doi: 10.1152/ajprenal.90559.2008. Epub 2009 May 6.

Supplemental Content

Loading ...
Support Center